<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02286206</url>
  </required_header>
  <id_info>
    <org_study_id>H14-01644</org_study_id>
    <nct_id>NCT02286206</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Dosing on Clozapine Levels</brief_title>
  <acronym>PK-CLZ</acronym>
  <official_title>A Pilot Study to Determine How Frequency of Administration Modifies Steady-State Plasma Concentrations of Orally Administered Clozapine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this 15-day study are:&#xD;
&#xD;
        1. To compare steady-state trough plasma concentrations of clozapine and its metabolite&#xD;
           norclozapine when given once daily and twice daily (at the same total daily dose)&#xD;
&#xD;
        2. To determine if frequency of clozapine administration has an effect on:&#xD;
&#xD;
             1. Symptoms of schizophrenia&#xD;
&#xD;
             2. Adverse effects of clozapine&#xD;
&#xD;
             3. Fasting blood glucose, lipids, creatinine, and urea&#xD;
&#xD;
             4. Weight and waist circumference&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is important that clinicians do everything possible to optimize the use of clozapine in&#xD;
      individuals with treatment-resistant schizophrenia. To our knowledge, there are no published&#xD;
      studies evaluating whether twice daily administration of clozapine is better than once daily&#xD;
      administration in terms of effectiveness and tolerability. Although this may seem trivial at&#xD;
      first, when we consider that clozapine has a relatively short half-life and dissociates&#xD;
      quickly from the dopamine D2 receptor, it justifies further consideration. It takes on even&#xD;
      more significance knowing that the established threshold clozapine plasma concentration for&#xD;
      therapeutic response (i.e., 350-420 ng/ml) was determined using steady-state trough plasma&#xD;
      samples (i.e., approximately 12 hours after the evening dose) in patients administered&#xD;
      clozapine twice rather than once daily.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in steady-state trough plasma concentrations of clozapine and norclozapine at Days 7 and 14.</measure>
    <time_frame>Days 0 (baseline), 7, and 14</time_frame>
    <description>Steady-state trough plasma concentrations of clozapine and norclozapine will be measured on Days 7 and 14 and compared to those obtained on Day 0 (baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in symptoms at Day 14.</measure>
    <time_frame>Day 0 (baseline) and 14</time_frame>
    <description>As assessed by structured clinical interviews for the Positive and Negative Syndrome Scale (PANSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in side effect burden at Day 14</measure>
    <time_frame>Days 0 (baseline) and 14</time_frame>
    <description>As assessed by the Udvalg for Kliniske Unders√∏gelser (UKU) Side Effect Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in laboratory measures at Day 14.</measure>
    <time_frame>Days 0 (baseline) and 14</time_frame>
    <description>Laboratory measures include fasting blood glucose, fasting lipid profile, creatinine, and urea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weight and waist circumference at Day 14.</measure>
    <time_frame>Days 0 (baseline) and 14</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Psychotic Disorders</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Clozapine bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants have been taking clozapine once daily and have reached steady-state prior to the start of this study.&#xD;
Intervention: Days 1-14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <description>One-half baseline dose po bid (or one-third baseline dose po qam and two-thirds baseline dose po qhs at the discretion of the treating clinicians and principal investigator)</description>
    <arm_group_label>Clozapine bid</arm_group_label>
    <other_name>Clozaril</other_name>
    <other_name>FazaClo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be between the ages of 19 - 65&#xD;
&#xD;
          -  Participants must be fluent in English&#xD;
&#xD;
          -  Participants must have a psychiatric diagnosis and are currently treated with&#xD;
             clozapine once daily in the evening&#xD;
&#xD;
          -  Participants must be on a stable dose of clozapine for at least one week to ensure&#xD;
             steady-state has been achieved&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who are hypersensitive to clozapine&#xD;
&#xD;
          -  Participants who are pregnant or lactating&#xD;
&#xD;
          -  Participants who are of childbearing age and not using reliable contraception&#xD;
&#xD;
          -  Participants who have postsurgical complications of the gastrointestinal tract that&#xD;
             might impair absorption&#xD;
&#xD;
          -  Participants who have any clinically relevant abnormalities of laboratory parameters&#xD;
&#xD;
          -  Participants who have had a potent CYP1A2 metabolic inducer (e.g., carbamazepine;&#xD;
             rifampin) or inhibitor (e.g., amiodarone; cimetidine; efavirenz; fluoroquinolone&#xD;
             antibiotics; ticlopidine) added to and/or removed from their medication regimen in the&#xD;
             past two weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ric M. Procyshyn, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alasdair Barr, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Honer, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Randall White, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UBC Hospital - Detwiller Pavilion</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 4, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2014</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Ric Procyshyn</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Clozapine</keyword>
  <keyword>Psychotropic Drugs</keyword>
  <keyword>Antipsychotic Agents</keyword>
  <keyword>Psychotic Disorders</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Adverse Effects</keyword>
  <keyword>Drug Monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

